Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 10,624 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Primary Malignant Brain Tumors
Interventions: CAU+ (Enhanced Care as Usual), Beating the Blues, SmartCare; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Malignant Melanoma
Interventions: HSPPC-96 or Oncophage; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 32 more

Conditions: Cystic Fibrosis, Colorectal Cancer, Adenoma
Interventions: Stool tests; Procedure
Lead sponsor: University of Washington, the Collaborative Health Studies Coordinating Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 26
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 21 more

Conditions: B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Chronic Lymphocytic Leukemia, Transformed Lymphoma
Interventions: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous); Drug
Lead sponsor: John Lister; Other
Eligibility: 18 Years to 79 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2037
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alzheimer's Disease
Interventions: T-817MA-H, T-817MA-L, Placebo; Drug
Lead sponsor: FUJIFILM Toyama Chemical Co., Ltd.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 50
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 46 more

Conditions: Asthma
Interventions: GW685698X; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 94
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more

Conditions: Osteoarthritis, Hip, Rheumatoid Arthritis, Avascular Necrosis
Interventions: Not listed
Lead sponsor: Biomet Orthopedics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 4
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania • Fredericksburg, Virginia + 1 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BI 1015550, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 56
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 45 more

Conditions: Pulmonary Aspergillosis
Interventions: Opelconazole, Standard of Care; Drug
Lead sponsor: Pulmocide Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 17
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more

Conditions: Endometrial Cancer
Interventions: Selinexor, Matching Placebo for selinexor; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 55 more

Conditions: Aortic Aneurysm, Aortic Dissection, Aortic Rupture
Interventions: Thoraflex™ Hybrid Device; Device
Lead sponsor: Bolton Medical; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 12
States / cities: Palo Alto, California • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: Venous Thrombosis, Pediatrics
Interventions: Rivaroxaban (Xarelto, BAY59-7939); Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 16
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 11 more

Conditions: Anxiety Disorders, Generalized Anxiety Disorder
Interventions: Escitalopram; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Heart Transplant, Small Intestine Transplant, Kidney Transplant, Liver Transplant, EBV-Related PTLD, PTLDs
Interventions: transplant, Immunosuppressive Drugs; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 21 Years
Enrollment: 944 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 7
States / cities: Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 4 more

Conditions: Adolescent Behavior, Tobacco Use, E-Cig Use
Interventions: AD IT UP media literacy intervention, Usual health education curriculum; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 13 Years to 17 Years
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lung Transplant Failure and Rejection
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 13 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Stanford, California + 7 more

Conditions: T-Cell Neoplasm, Lymphoproliferative Disorders
Interventions: Pacritinib; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Duarte, California • Tampa, Florida • Ann Arbor, Michigan + 3 more

Conditions: Sickle Cell Disease
Interventions: Oxbryta® (voxelotor) 500mg Tablets; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 4 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 43
States / cities: Mobile, Alabama • Phoenix, Arizona • La Jolla, California + 24 more

Conditions: Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Juvenile Arthritis
Interventions: Total knee arthroplasty; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: Denver, Colorado • Pittsburgh, Pennsylvania • Virginia Beach, Virginia

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions: NX-5948; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 28
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 24 more

Conditions: Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
Interventions: Radiation Therapy, Temozolomide, Veliparib; Radiation · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 25 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 145
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more

Conditions: Hepatitis C, Heart Transplant, Cardiac Transplant
Interventions: sofosbuvir/velpatasvir; Drug
Lead sponsor: Mary E. Keebler, MD; Other
Eligibility: 18 Years to 71 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions: alosetron; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 190
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more

Conditions: Cardiovascular Disease
Interventions: Olpasiran, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 50 Years to 105 Years
Enrollment: 11,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 205
States / cities: Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 170 more

Search by objective public record fields.

SmartCare: Innovations in Caregiving Interventions

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

Colorectal Cancer Screening in Cystic Fibrosis

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.

A Clinical Investigation of the Balance® Microplasty™ Hip System

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Thoraflex™ Hybrid IDE Study

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Drug Therapy for Generalized Anxiety Disorder Among the Elderly

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

Media Literacy for High School Tobacco Prevention

Long Term Follow up of the LTOG Cohort

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Expanding the Pool in Orthotopic Heart Transplantation

Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events